Home › Companies › Foghorn Therapeutics Inc. › 2025-2026

Foghorn Therapeutics Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Foghorn Therapeutics Inc.’s Form 8-K, filed 2026-06-24 (Item 5.07 on EDGAR). Page generated 02 October 2026.

8Reported items
119Asset managers
868Fund votes
2026-06-24Meeting date

Proxy season: 2025-2026

Explore Foghorn Therapeutics Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Foghorn Therapeutics Inc.

These tallies are Foghorn Therapeutics Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-24 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Foghorn Therapeutics Inc. — official shareholder meeting results, meeting held 2026-06-24
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Douglas Cole, M.D.	35,118,798	10,987,092	5,562	--	5,597,444	Majority: yes
Elect Director: Simba Gill, Ph.D.	45,956,872	151,145	3,435	--	5,597,444	Majority: yes
Elect Director: B. Lynne Parshall	44,412,258	1,695,530	3,664	--	5,597,444	Majority: yes

Source: Foghorn Therapeutics Inc., Form 8-K, filed with the SEC on 2026-06-24 — read the filing on EDGAR.

How asset managers voted at the Foghorn Therapeutics Inc. 2025-2026 meeting

Each item below shows how the 119 asset managers that disclosed a Foghorn Therapeutics Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Foghorn Therapeutics Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF FOGHORN'S NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

98% fund support · no official result

FOR 98%

The 113 asset managers below cast 98% of the shares they voted on this item FOR (28,340,242 for, 489,225 against).

FOR: 28,340,242 (98.3%)AGAINST: 489,225 (1.7%)

Largest asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF FOGHORN'S NAMED EXECUTIVE OFFICERS.” at Foghorn Therapeutics Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	9,874,799	0	For
BVF INC/IL	5,842,000	0	For
DEERFIELD MANAGEMENT COMPANY, L.P.	4,394,367	0	For
BlackRock	1,990,800	890	For
Vanguard	1,989,541	1	For
GEODE CAPITAL MANAGEMENT, LLC	849,481	0	For
Siren, L.L.C.	712,794	0	For
State Street	575,023	702	For
Candriam S.C.A.	0	313,765	Against
Northern Trust	265,144	0	For
AMERIPRISE FINANCIAL INC	255,755	0	For
Charles Schwab	207,026	0	For
SCS Capital Management LLC	113,736	0	For
DAFNA Capital Management LLC	111,859	0	For
MELLON INVESTMENTS Corp	109,846	0	For
JACOBS LEVY EQUITY MANAGEMENT, INC	92,932	0	For
Equitable	75,021	0	For
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0	74,600	Against
BRIDGEWAY FUNDS INC	0	68,000	Against
Goldman Sachs	67,208	0	For
STATE OF WISCONSIN INVESTMENT BOARD	66,563	0	For
T. Rowe Price	53,224	0	For
Nuveen	50,394	0	For
TIAA	49,073	0	For
QUANTITATIVE MASTER SERIES LLC	43,623	0	For

Showing the 25 largest of 113 asset managers. See all 113 in the interactive database.

2. TO APPROVE, ON AN ADVISORY BASIS, THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION OF FOGHORN'S NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

99% fund support · no official result

ONE YEAR 52.2%1 YEAR 28%1-YR 20%

The 113 asset managers below cast 99% of the shares they voted on this item FOR (10,314 for, 140 against).

FOR: 10,314 (0.0%)AGAINST: 140 (0.0%)ONE YEAR: 15,036,953 (52.2%)1 YEAR: 7,939,997 (27.5%)1-YR: 5,842,000 (20.3%)1.0: 63 (0.0%)3.0: 1 (0.0%)

Largest asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION OF FOGHORN'S NAME” at Foghorn Therapeutics Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Fidelity	0	0	0	0	One Year
BVF INC/IL	0	0	0	0	1-Yr
DEERFIELD MANAGEMENT COMPANY, L.P.	0	0	0	0	1 Year
BlackRock	0	0	0	0	1 Year
Vanguard	0	0	0	0	One Year
GEODE CAPITAL MANAGEMENT, LLC	0	0	0	0	One Year
Siren, L.L.C.	0	0	0	0	1 Year
State Street	0	0	0	0	One Year
Candriam S.C.A.	0	0	0	0	One Year
Northern Trust	0	0	0	0	1 Year
AMERIPRISE FINANCIAL INC	0	0	0	0	One Year
Charles Schwab	0	0	0	0	1 Year
SCS Capital Management LLC	0	0	0	0	One Year
DAFNA Capital Management LLC	0	0	0	0	1 Year
MELLON INVESTMENTS Corp	0	0	0	0	One Year
JACOBS LEVY EQUITY MANAGEMENT, INC	0	0	0	0	1 Year
Equitable	0	0	0	0	One Year
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0	0	0	0	One Year
BRIDGEWAY FUNDS INC	0	0	0	0	One Year
Goldman Sachs	0	0	0	0	One Year
STATE OF WISCONSIN INVESTMENT BOARD	0	0	0	0	One Year
T. Rowe Price	0	0	0	0	One Year
Nuveen	0	0	0	0	One Year
TIAA	0	0	0	0	One Year
QUANTITATIVE MASTER SERIES LLC	0	0	0	0	1 Year

Showing the 25 largest of 113 asset managers. See all 113 in the interactive database.

3. Elect Class III directors each for a three-year term: B. Lynne Parshall

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 44,412,258AGAINST: 1,695,530

Foghorn Therapeutics Inc.’s own tally for this item (“Elect Director: B. Lynne Parshall”): 44,412,258 for, 1,695,530 against, per its Form 8-K filed 2026-06-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 58,713,922 outstanding shares: 76% for, 3% against (79% of the company cast a for/against vote).

The 37 asset managers below cast 97% of the shares they voted on this item FOR (7,223,735 for, 242,154 against).

FOR 97%

FOR: 7,223,735 (96.8%)AGAINST: 242,154 (3.2%)

Largest asset managers voting on “Elect Class III directors each for a three-year term: B. Lynne Parshall” at Foghorn Therapeutics Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	3,935,922	0	For
Vanguard	1,729,823	4,597	For
BlackRock	1,169,164	0	For
Charles Schwab	103,502	0	For
Equitable	55,881	19,140	For
BRIDGEWAY FUNDS INC	0	68,000	Against
TIAA	0	49,073	Against
QUANTITATIVE MASTER SERIES LLC	43,623	0	For
Nationwide	7,437	32,624	Against
Columbia Threadneedle	28,105	0	For
Goldman Sachs	27,548	0	For
Northern Trust	25,133	0	For
Lincoln Financial	20,000	0	For
AIG/SunAmerica	0	16,607	Against
Global X	15,048	0	For
Pacific Life	13,626	0	For
CLEARWATER INVESTMENT TRUST	0	13,584	Against
PACE SELECT ADVISORS TRUST	0	12,480	Against
State Street	11,060	0	For
Bridge Builder Trust	10,778	0	For
Invesco	8,130	0	For
ProShares	0	7,658	Against
Voya	6,490	0	For
DWS	0	5,062	Against
T. Rowe Price	4,268	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

4. Elect Class III directors each for a three-year term: Balkrishan (Simba) Gill, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%

FOR: 45,956,872AGAINST: 151,145

Foghorn Therapeutics Inc.’s own tally for this item (“Elect Director: Simba Gill, Ph.D.”): 45,956,872 for, 151,145 against, per its Form 8-K filed 2026-06-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 58,713,922 outstanding shares: 78% for, 0.3% against (79% of the company cast a for/against vote).

The 37 asset managers below cast 99.6% of the shares they voted on this item FOR (7,443,488 for, 22,402 against).

FOR 99.6%

FOR: 7,443,488 (99.7%)AGAINST: 22,402 (0.3%)

Largest asset managers voting on “Elect Class III directors each for a three-year term: Balkrishan (Simba) Gill, Ph.D.” at Foghorn Therapeutics Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	3,935,922	0	For
Vanguard	1,731,339	3,082	For
BlackRock	1,169,164	0	For
Charles Schwab	103,502	0	For
Equitable	55,881	19,140	For
BRIDGEWAY FUNDS INC	68,000	0	For
TIAA	49,073	0	For
QUANTITATIVE MASTER SERIES LLC	43,623	0	For
Nationwide	40,061	0	For
Columbia Threadneedle	28,105	0	For
Goldman Sachs	27,548	0	For
Northern Trust	25,133	0	For
Lincoln Financial	20,000	0	For
AIG/SunAmerica	16,607	0	For
Global X	15,048	0	For
Pacific Life	13,626	0	For
CLEARWATER INVESTMENT TRUST	13,584	0	For
PACE SELECT ADVISORS TRUST	12,480	0	For
State Street	11,060	0	For
Bridge Builder Trust	10,778	0	For
Invesco	8,130	0	For
ProShares	7,658	0	For
Voya	6,490	0	For
DWS	5,062	0	For
T. Rowe Price	4,268	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

5. Elect Class III directors each for a three-year term: Douglas Cole, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

76% Majority: yes · of votes cast

FOR 76%AGAINST 24%

FOR: 35,118,798AGAINST: 10,987,092

Foghorn Therapeutics Inc.’s own tally for this item (“Elect Director: Douglas Cole, M.D.”): 35,118,798 for, 10,987,092 against, per its Form 8-K filed 2026-06-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 58,713,922 outstanding shares: 60% for, 19% against (79% of the company cast a for/against vote).

The 37 asset managers below cast 33% of the shares they voted on this item FOR (2,491,791 for, 4,974,098 against).

FOR 33%AGAINST 67%

FOR: 2,491,791 (33.4%)AGAINST: 4,974,098 (66.6%)

Largest asset managers voting on “Elect Class III directors each for a three-year term: Douglas Cole, M.D.” at Foghorn Therapeutics Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	722,040	3,213,882	Against
Vanguard	1,729,805	4,615	For
BlackRock	0	1,169,164	Against
Charles Schwab	0	103,502	Against
Equitable	0	75,021	Against
BRIDGEWAY FUNDS INC	0	68,000	Against
TIAA	0	49,073	Against
QUANTITATIVE MASTER SERIES LLC	0	43,623	Against
Nationwide	0	40,061	Against
Columbia Threadneedle	0	28,105	Against
Goldman Sachs	27,548	0	For
Northern Trust	0	25,133	Against
Lincoln Financial	0	20,000	Against
AIG/SunAmerica	0	16,607	Against
Global X	0	15,048	Against
Pacific Life	0	13,626	Against
CLEARWATER INVESTMENT TRUST	0	13,584	Against
PACE SELECT ADVISORS TRUST	0	12,480	Against
State Street	0	11,060	Against
Bridge Builder Trust	0	10,778	Against
Invesco	8,130	0	For
ProShares	0	7,658	Against
Voya	0	6,490	Against
DWS	0	5,062	Against
T. Rowe Price	4,268	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

6. TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATED

100% fund support · no official result

FOR 100%

The 36 asset managers below cast 100% of the shares they voted on this item FOR (7,452,306 for, 0 against).

FOR: 7,452,306 (100.0%)

Largest asset managers voting on “TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE ” at Foghorn Therapeutics Inc., 2025-2026
Asset manager	For	Vote
Fidelity	3,935,922	For
Vanguard	1,734,421	For
BlackRock	1,169,164	For
Charles Schwab	103,502	For
Equitable	75,021	For
BRIDGEWAY FUNDS INC	68,000	For
TIAA	49,073	For
QUANTITATIVE MASTER SERIES LLC	43,623	For
Nationwide	40,061	For
Columbia Threadneedle	28,105	For
Goldman Sachs	27,548	For
Northern Trust	25,133	For
Lincoln Financial	20,000	For
AIG/SunAmerica	16,607	For
Global X	15,048	For
Pacific Life	13,626	For
PACE SELECT ADVISORS TRUST	12,480	For
State Street	11,060	For
Bridge Builder Trust	10,778	For
Invesco	8,130	For
ProShares	7,658	For
Voya	6,490	For
DWS	5,062	For
T. Rowe Price	4,268	For
SEI	4,200	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

7. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 90%10%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (14,584 for, 0 against).

FOR: 14,584 (89.9%)ABSTAIN: 1,641 (10.1%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at Foghorn Therapeutics Inc., 2025-2026
Asset manager	For	Abstain	Vote
CLEARWATER INVESTMENT TRUST	13,584	0	For
ALGERT GLOBAL LLC	0	1,641	Abstain
TD Waterhouse Canada Inc.	1,000	0	For

8. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 93%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (13,584 for, 0 against).

FOR: 13,584 (93.1%)ONE YEAR: 1,000 (6.9%)

Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at Foghorn Therapeutics Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
CLEARWATER INVESTMENT TRUST	13,584	0	0	0	For
TD Waterhouse Canada Inc.	0	0	0	0	One Year

Largest Foghorn Therapeutics Inc. shareholders voting in 2025-2026

Ranked by the number of Foghorn Therapeutics Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 58,713,922 shares outstanding at the time of that meeting.

Top Foghorn Therapeutics Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Fidelity	16.82%
2	BVF INC/IL	9.95%
3	DEERFIELD MANAGEMENT COMPANY, L.P.	7.48%
4	BlackRock	3.39%
5	Vanguard	3.39%
6	GEODE CAPITAL MANAGEMENT, LLC	1.45%
7	Siren, L.L.C.	1.21%
8	State Street	0.98%
9	Candriam S.C.A.	0.53%
10	Northern Trust	0.45%

Reported Foghorn Therapeutics Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Foghorn Therapeutics Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Noubar Afeyan	35.38%	13D
Funds affiliated with Flagship Pioneering, Inc.	29.20%	DEF14A
Entities affiliated with Fidelity Investments	10.96%	DEF14A
Entities affiliated with Biotechnology Value Fund	10.38%	DEF14A
FMR (Fidelity)	10.30%	13F
BVF PARTNERS L P/IL	9.99%	13G
Deerfield Mgmt, L.P.	8.75%	13G
Eli Lilly and Company	6.81%	DEF14A
Deerfield Partners LP	6.27%	DEF14A
Cigall Kadoch, Ph.D.	6.22%	DEF14A

Percentages above are of 58,713,922 shares outstanding, as reported by Foghorn Therapeutics Inc. on its Form 10-Q dated 2026-04-30 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Foghorn Therapeutics Inc.’s 10-Q dated 2026-04-30. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Foghorn Therapeutics Inc.'s shareholder meeting held 2026-06-24, in the 2025-2026 proxy season, 119 asset managers reported how they voted in their SEC Form N-PX filings, covering 868 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Foghorn Therapeutics Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF FOGHORN'S NAMED EXECUTIVE OFFICERS. — the reporting funds cast 98% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Foghorn Therapeutics Inc. proxy season coverage: 2025-2026 (this page).